Brian Underdown

TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma). TM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies. In addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs.

DC Bio Corp. develops technology for application to cancer and diseases associated with chronic viral infections. The company is headquartered in Halifax, Canada.

PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada.

Cytochroma, Inc. is a clinical-stage specialty pharmaceutical company. It develops and markets prescription products for the prevention of vitamin D insufficiency. The firm specializes in pharmaceutical products to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease. The company was founded by Martin J. Petkovich in 1996 and is headquartered in Markham, Canada.

Protiva Biotherapeutics, Inc. develops pharmaceutical products for human diseases. The firm offers drugs for cancer, influenza (including H5N1), Ebola, inflammatory diseases and other chronic viral infections. The company was founded in September, 2000 and is headquartered in Seattle, WA.

Ellipsis Neurotherapeutics, Inc. develops pharmaceutical products for treatment and preventing of Alzheimer's disease and related disorders. The firm commercializes neurodegenerative disease therapeutics and diagnostics. The company was founded by Laurence Rubin in November 2004 and is headquartered in Toronto, Canada.

ID Biomedical Corp. develops gene-based disease testing and subunit vaccines. It conducts research, development, manufacturing, sales, and marketing from its facilities in Canada and in the United States. The company was founded in 1991 and is headquartered in Vancouver, Canada.

Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis.

MedTech Partners, Inc. provides investment services. The firm offers investment services to develop and commercialize early-stage biomedical innovations. The company is headquartered in Nepean, Ontario.

Argos Therapeutics, Inc. was a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and was headquartered in Durham, NC.

Bristol-Myers Squibb FCT bêta, Inc. operates as a biopharmaceutical firm. It develops anti-tumor activity medication treatment. The company was founded by Ilia A. Tikhomirov in 2011 and is headquartered in Toronto, Canada.

OsteoqQC, Inc. develops drugs for the treatment of bone-related diseases. The company was founded by Debra Ellies and is headquartered in Montreal, Canada.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Naegis Pharmaceuticals, Inc. manufactures pharmaceutical products. The private company is based in Vancouver, Canada.

Kisoji Biotechnology, Inc. operates as a biotechnology company which develops cancer therapeutics through antibodies and stem cells. The company was founded by David S. Young and is headquartered in Montreal, Canada.

Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada.

enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada.

Mcmaster Innovation Park operates as a premier research park that offers collaborative space for researchers and entrepreneurs to co-locate, connect and commercialize. The company is headquartered in Hamilton, Canada.

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.